AIM
TTNP

Acrospire Investment Management’s Titan Pharmaceuticals TTNP Stock Holding History

Acrospire Investment Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Hold
0
– -$3K – 1334
2017
Q2 		– Sell
-6
Closed -$55.8K – 2037
2017
Q1 		$75K Sell
6
-7
-54% -$98.4K 0.06% 548
2016
Q4 		$191K Buy
13
+4
+44% +$67.3K 0.08% 392
2016
Q3 		$181K Buy
+9
New +$175K 0.12% 203
2016
Q2 		– Hold
0
– – – 1817

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acrospire Investment Management's TTNP Position: Q3 2017 in Review

Acrospire Investment Management held its Titan Pharmaceuticals (TTNP) position steady in Q3 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1334.

Acrospire Investment Management first reported a position in TTNP in Q3 2016 and has held it in 3 quarters since. The position peaked at $191K in Q4 2016. 24 funds tracked by Wall St. Rank hold TTNP as of Q3 2017.

  • Acrospire Investment Management held 0 shares of Titan Pharmaceuticals worth $0 as of Q3 2017.
  • Acrospire Investment Management left its Titan Pharmaceuticals share count unchanged in Q3 2017.
  • Titan Pharmaceuticals made up ﹤0.01% of Acrospire Investment Management's portfolio in Q3 2017, its #1334 holding.
  • Acrospire Investment Management first reported a position in Titan Pharmaceuticals in Q3 2016 and has held it in 3 quarters since.
  • Acrospire Investment Management's Titan Pharmaceuticals position peaked at $191K in Q4 2016.
  • 24 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.